According to the latest study from BCC Research, the demand for Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets is projected to grow from $4.6 billion in 2024 to $13.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.3% during the forecast period of 2024 to 2029.
This liquid biopsy market report offers a comprehensive analysis of the global liquid biopsy market, covering tools, services, and diagnostics. It includes market trends, estimates, and CAGR forecasts from 2024 to 2029, using 2023 as the base year. The study explores industry structure, competitive dynamics, key players, product offerings, financials, and strategies. It segments the market by application, analysis purpose, biomarker type, and platform. Regional insights span North America, Europe, Asia-Pacific, South America, and the Middle East and Africa.
Interesting facts:
- Liquid biopsies (LBx), primarily used for genetic profiling and therapy selection, are now expanding into pharmaceutical research and enhancing various aspects of patient care.
- Advances in nanotechnology are driving the development of innovative sensors and systems for detecting and analyzing liquid biopsy biomarkers, potentially offering greater sensitivity and specificity than existing techniques.
Factors contributing to the market’s growth include:
- Advances in liquid biopsy workflow technologies: These are making it easier and faster to detect disease-related biomarkers in blood or other fluids. These improvements enhance accuracy, reduce processing time, and enable earlier diagnosis and better treatment monitoring.
- Increasing incidence of cancer: This is due to the world’s aging populations, lifestyle changes, and environmental influences. This growing incidence highlights the need for better screening, early detection, and advanced treatment options.
- Growing awareness of early cancer detection: More people are learning about the importance of detecting cancer early, which can lead to better treatment outcomes. Awareness campaigns and improved screening methods are helping to catch cancer in its early stages.
- Limitations of tissue biopsy: Tissue biopsies are invasive procedures that can be painful and risky, requiring surgery or needle extraction. They may also miss tumor changes over time, making it harder to track disease progression accurately.
- Growing significance of precision medicine: Precision medicine tailors’ treatments to a person’s unique genes and disease characteristics. This approach helps improve treatment effectiveness and reduces side effects.
- Emerging economies: Emerging economies, such as India and Brazil, are experiencing rapid economic growth and development. Advances in the improving industries, healthcare, and infrastructure are creating new opportunities.
Report Synopsis
|
Report Metric |
Details |
|
Base year considered |
2023 |
|
Forecast period considered |
2024-2029 |
|
Base year market size |
$3.8 billion |
|
Market size forecast |
$13.1 billion |
|
Growth rate |
CAGR of 23.3% for the forecast period of 2024-2029 |
|
Segments covered |
Application, purpose of analysis, biomarker type, platform, and region |
|
Regions covered |
North America, Europe, Asia-Pacific, and the Rest of the World (South America and the Middle East and Africa) |
|
Countries covered |
U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, China, India, Japan |
|
Market drivers |
• Advances in liquid biopsy workflow technologies. • Increasing incidence of cancer. • Growing awareness of early cancer detection. • Limitations of tissue biopsy. • Growing significance of precision medicine. • Emerging economies. |
Questions addressed:
1. What is the projected market size and growth rate?
The global market for liquid biopsy research tools, services and diagnostics was estimated at $4.6 billion in 2024. It is projected to reach $13.1 billion by the end of 2029, at a CAGR of 23.3% from 2024 to 2029.
2. What segments are covered in the market?
The market segments covered include applications for cancer, and non-invasive prenatal screening. Based on biomarker type and analysis platforms, the market segments include cell free nucleic acids, circulating tumor cells, and NGS, and PCR.
3. Which application type will be dominant throughout the forecast period?
Non-invasive prenatal screening (NIPT) will be the dominant application type.
4. Which region has the largest market share?
North America holds the largest share of the market.
Market leaders include:
- Bio-Rad Laboratories Inc.
- Bio-Techne
- Dxcover Ltd.
- Exact Sciences Corp.
- F. Hoffmann-La Roche Ltd.
- Freenome
- Guardant Health
- Illumina Inc.
- Myriad Genetics Inc.
- Natera Inc.
- Neogenomics Laboratories
- Novigenix SA
- Personalis Inc.
- Qiagen
- Thermo Fisher Scientific Inc.
